Quantcast
Last updated on April 16, 2014 at 10:52 EDT

Latest Patau syndrome Stories

2014-01-16 16:24:23

DUBLIN, January 16, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/322q6g/noninvasive) has announced the addition of the "Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/322q6g/noninvasive ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Non-invasive prenatal...

2012-09-24 02:27:17

SAN JOSE, Calif., Sept. 24, 2012 /PRNewswire/ -- A new study published in the journal Ultrasound in Obstetrics and Gynecology, is the largest study to date of non-invasive prenatal testing (NIPT) for detecting fetal trisomy 13 (T13) and provides further evidence of the Harmony Prenatal Test's utility for detection of genetic conditions. T13 causes Patau syndrome and affects approximately one in 16,000 newborns. T13 is also associated with a high rate of spontaneous miscarriage. (Logo:...

2012-07-02 02:23:58

REDWOOD CITY, Calif., July 2, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced that its non-invasive verifi(TM) prenatal test can now be used to detect Turner syndrome (monosomy X or XO), a genetic condition in which a person has one X chromosome and is missing a second sex chromosome. Turner syndrome affects approximately one in every 2,000 female births. (Logo:...

2012-05-18 02:24:08

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company announces that...

2012-04-25 02:32:23

REDWOOD CITY, Calif., April 25, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the peer-reviewed publication of a new health economic model for its verifi(TM) prenatal test that clearly demonstrates the clinical and economic value of integrating the verifi(TM) prenatal test into current prenatal screening algorithms. The model shows a dramatic reduction in both the number and cost of invasive...

2012-02-23 07:00:00

REDWOOD CITY, Calif., Feb. 23, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today published the full data from its prospective, blinded, multicenter clinical validation study to detect fetal chromosomal aneuploidies across the entire genome, including cases of fetal mosaicism and translocations. The publication, entitled "Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing," was selected as Editor's Choice...

2012-02-13 09:00:00

REDWOOD CITY, Calif., Feb. 13, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the presentation of top-line results from its prospective, blinded, multicenter validation study to detect fetal chromosomal aneuploidies, or an abnormal number of chromosomes, across the entire genome. The study was specifically designed to include all samples with any abnormal karyotype in order to emulate real-world testing in which...

2012-02-02 15:00:00

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication of an independent multi-center study on Sequenom Center for Molecular Medicine's MaterniT21(TM) laboratory-developed test (LDT) appears today in the online issue of Genetics in Medicine. The study demonstrated the LDT can detect fetal trisomy 21, 18 and 13 with high accuracy from a maternal blood sample and will...

2010-06-30 03:49:00

LONDON, June 30 /PRNewswire/ -- Frost & Sullivan is pleased to announce that it has awarded its prestigious 2010 Scandinavia New Product Innovation Award to FCMB ApS ("FCMB") for its breakthrough work in non-invasive prenatal testing. FCMB is developing a suite of non-invasive prenatal diagnostics based on isolating fetal cells from maternal blood samples. FCMB's diagnostics have the potential to provide results that are as accurate as more invasive procedures, such as amniocentesis...

2009-09-17 09:17:52

A Florida State University scientist says he's found the cause of chromosomal birth defects, such as Down, XYY, Edwards, Patau and Turner's syndromes. Using yeast genetics, Assistant Professor Hong-Guo Yu and colleagues selectively removed a single protein from the cell division process called meiosis and found that when the protein known as Pds5 is missing, chromosomes fail to segregate and pair up properly, and birth defects can result. Researchers said the study shines new light on the...